The purpose of this study was to measure the trajectory of psychosocial recovery over the first year after bone marrow transplantation (BMT). BMT patients were assessed at baseline (n = 86), hospital discharge (n = 74), 100 days (n = 64) and at 1 year (n = 45). Participants completed the Functional Assessment of Cancer Therapy-Bone Marrow Transplant Scale (FACT-BMT), the Profile of Mood States Total Mood Disturbance Scale (POMS-TMDS), the Medical Outcomes Social Support Survey (MOS-SSS), the Center for Epidemiologic Studies-Depression (CES-D) scale screener, a performance Status Rating Scale (PSR), and an interview questionnaire. The recovery trajectory in this patient population showed three distinct trends. The trajectory for distress was linear and improved over time with approximately 20% of patients continuing to have psychological distress at 1 year. Secondly, the trend for overall quality of life was parabolic, worsening at discharge, then improving at 100 days and at 1 year. However, there were individual areas of deficit at follow-up, eg fatigue, even while overall quality of life mean scores improved. Thirdly, the trend for patient concerns over time was linear and worsening. These recovery trajectories suggest psychosocial interventions before and after BMT that may prepare patients for increasing and worsening concerns even as physical well-being improves. Keywords: quality of life; psychological distress; bone marrow transplantation
ies. [5] [6] [7] [8] [9] [10] [11] [12] More recently, studies that employ a prospective longitudinal design measuring quality of life (QOL) both before and at multiple time points after transplantation have been utilized. [13] [14] [15] [16] Several comprehensive reviews of the literature provide an overview of the numerous studies conducted to date. [17] [18] [19] [20] Even with a developing consensus that post-BMT functioning can be satisfactory for most survivors, questions remain about how quickly patients recover a life of quality following BMT. For example, what concerns and problems do recipients experience in returning to normal during the 1 year time period post-BMT? 21, 22 Our understanding of post-bone marrow transplant functioning has benefited greatly from surveys completed by patients following transplantation. However, patients who are assessed at variable time points months to years after transplantation do not represent a homogenous group. There is some evidence of a trajectory of recovery over the first year following transplantation. Patients may experience additional gains in functioning up to 2 years post-BMT and then 'level off'. 14, 21 Patients who are surveyed at various time points, especially during the first year after BMT, may be in very different stages of recovery. Much of the evidence on QOL after BMT comes from survivors who are many months or years post-transplantation. 20 Generally, patients who survive more than 2 years are likely to achieve a reasonable adjustment and satisfactory quality of life. In one study, more than 80% of transplant patients reported satisfaction with overall QOL at 1 year. 15 Evaluating the trajectory of recovery following BMT is only possible through a prospective longitudinal design in which all patients are assessed at particular time points following BMT. Several studies have utilized this type of design. Syrjala and colleagues 14 assessed 67 allogeneic BMT patients prior to hospital admission, 90 days after transplantation (n = 34), at 1 year post-transplant (n = 31), and at 2 years and 4 to 6 years following transplantation. Functioning was most impaired at 90 days following transplantation and at 1 year more than 50% of the patients reported functioning well both physically and psychosocially. However, 27 and 30% of subjects reported mild to moderate levels of depression pre-transplant and at 1 year, respectively.
A second study surveyed a total of 58 disease-free or relapsed autologous BMT patients at 90-day intervals over the first year after BMT. 15 At 90 days a significant number of patients (from 32 to 55%) had many physical concerns, 50% were unemployed, 13% were not satisfied with sexual functioning, and 27% reported feeling bad about their appearance. The mean score on the single quality of life item used was recorded as 'above average'. In general there were adjustment problems for a significant percentage of patients in a number of areas within 90 days following transplantation.
Andrykowski and colleagues 13 assessed QOL in 28 BMT patients prior to hospital admission and from 12-16 months after BMT. Analysis of group means on the quality of life measures indicated few differences between pre-and post-BMT assessments. Further analysis of difference scores revealed that the physical and psychosocial status of some patients improved following BMT and declined for others. Specific areas of recorded deficits were in the area of sexual relationships and vigor.
Refinement of the definition of QOL and improvements in instruments to measure this construct has evolved along with BMT medical technology. Most researchers now agree that it is necessary to measure physical, emotional, functional and social domains to assess adequately health related QOL. [23] [24] [25] Two instruments specifically designed to measure BMT patient QOL have been published. 26, 27 Additionally, one instrument has been reported as under development. 28 The goal of this study was to assess 'transition points' or critical time periods where patient functioning might be expected to be compromised, utilizing a QOL instrument that has been standardized on a BMT patient population. Both clinical observation and previous research 9, 22 have indicated that hospital discharge, 100 days and 1 year represent important time points post-BMT. We chose followup assessment points at discharge in order to validate empirically clinical observation of compromised QOL at this point, 100 days because this time point has been associated with decreased medical surveillance, and 1 year because it represents an anniversary of a highly significant time point in the patient's life and a time when patients would expect to return to some semblance of normality.
The prospective longitudinal design used in this study allowed us to plot what has been referred to as the 'temporal trajectory' of BMT patients over 1 year. 9 This design, utilizing QOL and psychological measures, allowed for the identification of a recovery trajectory over time. It could be that emotional, physical and functional areas of QOL recover at different rates or trajectories. It is likely that as patients recover physically, they may encounter different problems of adjustment with regard to functional activities such as work or recreation. There are two reasons why understanding the recovery trajectory following BMT is important. First, this information can be provided to patients prior to BMT so that their expectations for recovery after treatment are more accurate. There is evidence that discordance between expectations and what actually happens is associated with increased distress post-BMT. 21 Secondly, this information can be used to plan specific rehabilitation interventions at a time when the patient may need them most.
Specific research questions addressed were: (1) what are the overall quality of life and specific psychosocial or physical deficits reported by patients following transplantation relative to pre-transplantation functioning? (2) How do BMT patient's psychological distress and QOL vary over the first year post-transplant?
Patients and methods

Patients
All consecutively treated patients seen in the Comprehensive Cancer Center, Wake Forest University School of Medicine/NC Baptist Hospital Medical Center between 1 April 1994 and 15 March 1995 were eligible for the study. Patients were required to be english speaking, not currently under psychiatric treatment, able to comprehend the study and 18 years of age or older. A total of 100 patients were admitted to the hospital for bone marrow transplantation and invited to participate in the study during that time period. Fourteen patients declined to participate, resulting in a sample size of 86 patients at baseline. At discharge, seven patients had expired, three patients left the hospital before the interview could be conducted and failed to return mailed questionnaires, one patient refused and one patient provided only partial data, resulting in a sample of 74. At 100 days, six additional patients had expired and eight patients declined to participate. Four patients whose data were missing at discharge completed questionnaires at 100 days. At 1 year, 13 additional patients had expired, three patients were too sick to complete forms and one patient failed to complete the interview. One patient was excluded from the analysis because she had no pre-treatment quality of life data. A total of 42 subjects completed study questionnaires at each time point. All 86 participating patients were enrolled on one of eight transplantation protocols approved by the clinical research practices committee of the Wake Forest University School of Medicine. Cytoreductive therapy varied according to protocol. Thirty-six patients received cyclophosphamide, 120 mg/kg with total body irradiation, 1320 cGy in eight fractions (CyTBI); 28 received cyclophosphamide, 6 g/m , and total body irradiation, 1350 cGy in nine fractions. All received either 2-mercaptoethanesulfonate (Mesna) or continuous bladder irrigation to prevent hemorrhagic cystitis. All cytoreductive therapy was administered at the Bone Marrow Transplant Unit at North Carolina Baptist Hospital, and all patients remained hospitalized until hematopoietic engraftment.
Procedure and measures
On the day of hospital admission, prior to BMT, patients were invited to participate in the study. They were told that all BMT recipients were interviewed by a clinical psychologist and asked to complete several questionnaires prior to transplantation as a part of the admissions procedure. Bone marrow harvest and peripheral stem cell collection procedures had been completed prior to completion of the baseline assessment. Patients were asked to complete similar questionnaires at hospital discharge, 100 days and 1 year following transplantation. All study participants signed a consent form meeting all institutional, state and federal guidelines. Patients were then interviewed and given the study questionnaires described below. The procedure for completing each questionnaire was described by the interviewer who returned the following day to retrieve the completed forms. The interviewer checked all data and requested that patients complete items that had been omitted. At hospital discharge, study participants once again completed all the questionnaires with the exception of the Medical Outcome Study-Social Support Survey. In addition, they were interviewed by a research assistant (interviewer questionnaire) who inquired about a list of concerns identified by patients in previous research. 29 At approximately 100 days and 12 months following transplantation, participants were mailed questionnaire packets which included all instruments completed at baseline plus the interviewer questionnaire described below. Patients were instructed to complete the questionnaire in preparation for the research interviewer's telephone call. Subsequently, the research interviewer phoned the participants, clarified any questions and recorded patients' written responses and verbal comments during the interview.
Measures
The Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) Scale: 27 The general version of the Functional Assessment of Cancer Therapy (FACT-G) is a 28-item self-report questionnaire that measures quality of life in cancer patients. 30 The FACT consists of five subscales measuring physical (PWB), functional (FWB), social/family (SFWB), emotional well-being (EWB), and satisfaction with the doctor/patient relationship (RWD). The FACT can be either self-administered or used in an interview format and is easily completed in 5-10 min. The bone marrow transplant subscale (BMT) of the FACT includes 12 items specifically designed to test quality of life in bone marrow transplant patients. The FACT-BMT is the FACT-G plus the BMT subscale. Patients are asked to rate themselves on how they feel today and over the past 7 days. The FACT-BMT provides an overall quality of life score and has been validated on bone marrow transplantation patients. A higher score indicates better quality of life. Cronbach's alpha for each subscale has been reported as follows: PWB (0.84); FWB (0.78); SFWB (0.69); EWB (0.67); RWD (0.62); and BMT (0.62). 27 
The Profile of Mood States Total Mood Disturbance Scale (POMS-TMDS):
31 This measure is a shortened version of the 65-item POMS. It consists of 11 scored items (plus six non-scored items incorporated to reduce the negative mind set that can be produced by listing only mood negative words) that yield a total mood disturbance score that has been reported as correlating significantly with the longer POMS, r = 0.93. 31 A higher score indicates more distress.
The POMS-TMDS was chosen because it provides a brief measure of overall distress and requests that patients rate their mood over the past week.
Medical Outcome Study-Social Support Survey (MOS-SSS):
32 The social support survey is a 21-item scale designed to measure perceived functional support. Internalconsistency and 1-year stability coefficients (Cronbach's alpha) for the four subscales and overall index are: emotional/informational support, 0.96; tangible support, 0.92; positive interaction, 0.94; affection, 0.91; and the overall support index (0.97). Correlation (Cronbach's alpha) between the items and selected validity variables range from r = 0.74 to r = 0.93. It was used to measure any changes in perceived overall social support over time. A higher score indicates better overall social support.
The Center for Epidemiological Studies-Depression (CES-D) Scale Screener:
This is an eight-item scale that has been used to screen for depression in general and medical populations. 33 It consists of six items from the original 20-item CES-D and two items from the Diagnostic Interview Schedule. Each item was weighted and entered into a mathematical formula which identifies patients who score above a 'cut point' of 0.06. Patients who score above this point have significant depressive symptoms and are likely to have a depressive disorder. For six items, patients are asked to rate how they have felt over the past week.
The Eastern Cooperative Oncology Group (ECOG) Performance Status Rating Scale:
34 This is a single-item rating of activity level where 0 = fully ambulatory without symptoms; 1 = fully ambulatory with symptoms; 2 = requiring bed rest (or equivalent) less than 50% of the waking day; 3 = requiring bed rest (or equivalent) greater than 50% of the waking day; and 4 = bedridden. Like the Karnofsky Performance Index, it is a general measure of overall performance status. It is simpler to use than the Karnofsky scale and correlates highly with overall quality of life as measured by the FACT. 27, 30 A higher score indicates a decline in overall performance status.
Interviewer Questionnaire and additional items: An interviewer questionnaire was constructed by the authors as a supplement to the instruments chosen for the study. The questionnaire consisted of two parts. In part 1, patients were asked to indicate their degree of concern at the time of the interview for 12 specific items (employment, finances, changes in relationships with family, changes in relationship with significant others, relationships with friends, physical health, general frame of mind, appearance, health or life insurance, personal or intimate relations, ability to have children, planning for the future) and any other concerns not named. The questionnaire was adapted from a previous survey of cancer patients conducted by Stalker and colleagues. 29 Items were answered on a Likert scale with a range of response from 1 (no concern) to 5 (extremely concerned). In part 2, patients were asked about their satisfaction with medical care, expectations regarding treatment, and participation in counseling or support groups.
Statistical analysis
Descriptive and univariate statistics were calculated for all demographic variables recorded at hospital admission. Descriptive statistics and composite scores were calculated for the FACT-BMT and all subscales. Items on the POMS-TMDS were summed. On the MOS-SSS, subscale scores were totaled and reported as an overall score of patient perceived social support. The items on the CES-D scale screener were summed and scored according to a formula established by the developers of the scale. 33 Patients who scored above the established cut point were 'screened in' as at risk for depression. The number and percentage of patients reporting a concern at each time point was tabulated for the Interviewer Questionnaire. Repeated measures analysis of variance (ANOVA) were conducted for the FACT-BMT (and its subscales), and the POMS-TMDS to test for changes in scores over the four assessment periods. Where significant differences were found, pair-wise contrasts were used to test for the locus of these differences. Repeated measures ANOVA was also used to assess the change in patient concerns over time. Fishers exact test and the Wilcoxon rank sum test were used to test for differences on the outcome measures between the patients who had undergone autologous vs allogeneic transplantation.
Results
Patient characteristics at all time points are summarized in Table 1 . The majority of patients were treated for breast cancer (n = 32, 37%) or non-Hodgkin's lymphoma (n = 32, 37%). Eighty-one percent (n = 70) of the recipients received autologous bone marrow or peripheral stem transplantation or a combination of each and the remainder underwent allogeneic bone marrow transplantation. The mean length of hospital stay for surviving patients was 30.1 days (s.d. = 10.1; range = 18-63 days, n = 72). Sixteen (36%) patients had returned to full-time employment at 1 year. Patients who stayed in the study were compared with those who did not on the following characteristics: age, race, education, gender, marital status and type of transplant. The only differences between the group of patients who remained in the study over all time points (n = 42) and those who did not (n = 44) was with regard to educational level with drop-outs having slightly less education (x = 12.6 vs 14.3 years, P = 0.02) and type of transplant with more allogeneic patients failing to complete the study (P = 0.02).
Quality of life and energy level
Mean scores for the FACT-BMT QOL scale are reported in Table 2 . Repeated measures ANOVA yielded significant change in mean scores over time on the following: EWB, P = 0.0007; FWB, P = 0.0001; BMTS, P = 0.03; and the FACT-G (P = 0.03) from baseline to 1 year. Mean scores on FWB decreased from baseline to discharge but then show an increase at both 100 days and 12 months. At 1 year, this group reported improvement on PWB, EWB, FWB, and the overall FACT-BMT scale when compared with baseline.
We conducted post hoc analyses pair-wise comparisons to determine the locus of differences for each subscale with the following results, significant at the P Ͻ 0.01 level: EWB, baseline to discharge, baseline to 100 days and baseline to 1 year; FWB, baseline to discharge, discharge to 100 days, discharge to 1 year and 100 days to 1 year; BMTS, discharge to 100 days and discharge to 1 year; and the FACT-G, discharge to 1 year. In addition to the repeated measures ANOVA for all patients at all time points, we conducted the same analyses for the patients who were assessed at all time points (Table 3) . Overall effects for the group of 42 patients interviewed at each time point were significant on the same subscales as for the entire sample and also on the PWB and the FACT-BMT.
Several individual items on the FACT were analyzed separately due to their relevance for the BMT patient population (see Figure 1) . In each of these items the trend was toward better overall quality of life both at 100 days and 1 year with the exception of 'I tire easily'. At 100 days and 1 year, over 80% of this population reported 'tiring easily'. The proportion of patients reporting 'lack of energy' increased at discharge and then declined at 100 days and 1 year. The same pattern was seen for 'side-effects of treatment'. At 1 year, 87% of patients responded somewhat, quite a bit, or very much to the statement 'I am content with the quality of my life right now'. Of note, very few patients reported any doubts about their decision to undergo BMT. In response to the item, 'I regret having the BMT' patients responded 'not at all' at each time point as follows: baseline, n = 66 (83%); discharge, n = 73 (99%); 100 days, n = 57 (89%); 1 year, n = 42 (93%).
We conducted additional analyses to investigate whether length of hospital stay was related to any of the FACT subscales or total FACT score and found no significant relationships.
In order to look at change scores, the sample was divided into quartiles based on overall quality of life score at baseline. Patients who began in the lower quartile on overall QOL demonstrated a significant improvement in PWB, EWB, FWB and overall FACT-G scores at 1 year. Patients who began in the upper quartile maintained similar status over the course of the study on overall FACT scores and subscales.
Psychological distress and performance status
The measures of psychological distress were the CES-D screener scale and the POMS-TMDS. The following percentage of patients reported significant depressive symptoms on the CES-D screener: baseline (n = 21, 24%); discharge (n = 21, 28%); 100 days (n = 20, 32%); and 12 months (n = 9, 20%). Thirty-seven patients (43%) reported depressive symptoms at one or more time points over the 1 year of follow-up. Forty-nine patients (57%) did not report significant depressive symptoms at any time. Using repeated measures ANOVA we compared patients with depressive symptoms (scored above the cut point on the CES-D screener) at baseline and those without symptoms. There was an association between depressive symptoms and lower QOL (P Ͻ 0.001) over the course of the study, with those patients who reported depressive symptoms also reporting poorer overall QOL. The total scores on the POMS-TMDS declined over the 1 year period indicating less overall distress: baseline (x = 10.4, s.d. = 6.9); discharge (x = 8.9, s.d. = 8.6); 100 days (x = 7.7, s.d. = 8.0); 12 months (x = 6.9, s.d. = 6.5). Repeated measures ANOVA yielded statistically significant differences (P = 0.0056). Ad hoc pair-wise comparisons yielded statistically significant differences for baseline to 100 days and baseline to 1 year with patients improving over time. Performance status ratings by all patients at all time points are reported in Table 4 . The proportion of patients reporting normal activity decreased at 100 days and then showed a steady increase to 1 year.
Counseling, psychological distress and quality life
A total of 22 of 64 patients had participated in some form of counseling or a support group by day 100 or at 1 year. The 22 patients who had received some form of counseling were compared with those who had not on the FACT and POMS using repeated measures analysis of variance. While there were no statistically significant differences between the groups, the group receiving counseling did show a trend toward improved emotional functioning (EWB of the FACT) when baseline scores were compared with scores at 1 year. This same trend was also observed from 100 days to 1 year, that is a slight increase in mean scores on the Ratings were made by patients who were asked to place themselves in one of the following categories: 0 = I have normal activity; 1 = I have some symptoms, but I can walk and I do not spend any extra time in bed; 2 = I need some time in bed, but it is less than 50% of normal daytime; 3 = I need to be in bed greater than 50% of normal daytime; 4 = I am unable to get out of bed.
EWB subscale. Additionally, those who did not receive some form of counseling had decreased mean scores on the emotional well-being subscale. Univariate analysis of the POMS-TMDS yielded no statistically significant interactions between groups (counseling vs no counseling) and time. At baseline, the groups did not differ on overall dis-tress as measured by mean scores on the POMS-TMDS. At discharge, however, although not statistically significant, there was a 30% difference in mean scores (x = 11.4 (8.5), range = 0-31; x = 8.5 (9.1), range = 0-40) with those patients who would eventually receive counseling having higher mean scores. Over the course of time from discharge to 100 days to 1 year scores in both groups decreased to approach near identical scores at 1 year. The mean scores for the counseling vs no counseling groups were respectively: 100 days, x = 8.2 (8.0), range = 0-32 vs x = 7.4 (8.0), range = 0-30; 1 year, x = 6.7 (5.7), range = 0-18 vs 6.9 (7.1), range = 0-33. While not statistically significant, the mean distress scores in the group that received some type of counseling decreased more, suggesting that the counseling or support group intervention may have had some effect on mood.
Social support
Social support on the MOS-SSS was recorded for four dimensions and overall total score. The dimensions included positive social interaction (a sense of belonging or social companionship), emotional/informational support (guidance), affectional support (attachment or affection), and tangible support (material support and aid). Social support remained constant and relatively high over time with the exception of tangible support which decreased slightly from baseline to 100 days and from baseline to 1 year. Repeated measures analysis of variance yielded an overall significant effect for tangible support over the study period (P = 0.01) and on the total social support score (P = 0.046).
Ad hoc pair-wise comparisons on tangible support yielded decreases between baseline and 100 days (P = 0.02) and baseline and 1 year (P = 0.002) and overall social support from baseline to 1 year (P = 0.02). Figure 2 presents the data on patient concerns following transplantation. At 1 year, over 35% of patients indicated somewhat, quite a bit or very much concern in the following areas: job or work situation, finances, general physical health, general frame of mind, health or life insurance, personal or intimate physical relations, and planning for the future. In addition to listing the percentage of patients with concerns in specific areas, repeated measures ANOVA was conducted for each item rated by patients. A significant relationship between time and concern was observed for the following items with patients reporting increasing concern over time: job/work situation (P = 0.0391); significant other (P = 0.005); family changes (P = 0.0001); changes with friends (P = 0.0001); concern about finances (P = 0.011); physical health (P Ͻ 0.001); frame of mind (P Ͻ 0.001); insurance status (P = Ͻ0.01); intimate relations (P = Ͻ0.001); and planning for the future (P = Ͻ0.001).
Patient concerns after transplantation
At baseline, patients were asked to rate how difficult all their previous treatments had been for cancer by circling a number from 1 (not at all difficult) to 10 (very much so). At discharge, 100 days and 1 year, all patients were asked to rate the difficulty level of their bone marrow transplantation. At discharge, mean difficulty scores for the bone marrow transplant treatment were 6.8 (s.d. = 2.1) compared to 4.8 (s.d. = 2.1) for previous treatments (P Ͻ 0.0001). Similar differences were observed at 100 days and 1 year. At discharge a total of 24 (37.5%) patients rated their BMT experience at a difficulty level of 8 or greater. There were no statistically significant differences between patient ratings at each time point on individual protocols. Additionally, there were no statistically significant differences in difficulty ratings between allogeneic and autologous transplant recipients at discharge, 100 days or at 1 year.
Each patient was asked: 'Please rate your current energy level in comparison to what is normal for you ranging from 0-100%, 100% = normal for you'. Number of patients, mean scores (s.d.), and range of scores, were reported as follows at each time point with the overall P = 0.0001: discharge (n = 67, x = 45.8 (19.5), 0-99); 100 days (n = 63, x = 58.4 (21.0), 20-100); 12 months (n = 43, x = 69.7 (21.2), 8-100). All ad hoc comparisons between time points were significant (P Ͻ 0.01). This same relative relationship held when only those 38 patients with energy ratings at all time points were compared: discharge (x = 45.7 (18.0), 10-95); 100 days (x = 62.3 (20.5), 30-100); and 1 year (x = 70.1 (20.5), 8-100). Similar to the analysis with all patients, the effect over time was significant (P = 0.0001), with significant differences from discharge to 100 days and discharge to 1 year. The percentage of patients reporting 75% or greater of normal energy at each time point was: discharge, 10.5%; 100 days, 33.3%; 1 year, 51.0%.
Predicting QOL and distress
Multiple regression analysis was performed on demographic characteristics (age, race, education and gender) along with performance status and QOL at 1 year. The only variable associated significantly with improved overall QOL over the course of 1 year was performance status (P Ͻ 0.001) with patients who had a better performance status at baseline having higher FACT scores at 1 year. Also, using repeated measures ANOVA patients with depressive symptoms (scored above the cut point on the CES-D screener) at baseline and those without symptoms were compared. There was an association between depressive symptoms and lower QOL (P Ͻ 0.001) over the course of the study, with those patients who reported depressive symptoms also reporting poorer overall QOL.
Discussion
The recovery trajectory in this patient population shows three distinct trends. First, the trend for QOL (FACT-BMT) is parabolic, worsening at discharge then improving at 100 days and 1 year. However, mean energy levels as rated by patients are only at 70% at 1 year. Secondly, the trajectory for distress (POMS-TMDS, CES-D) is linear and improving over time with a subset of patients (approximately 20%) continuing to have problems at 1 year. Thirdly, the trend for patient concerns (Figure 2 ) is linear and worsening.
Overall quality of life (FACT-BMT) decreased at discharge, returned to baseline levels at 100 days and improved to greater than baseline levels at 1 year. There was a general trend toward improvement that continued through 1 year following the decrease in overall QOL at discharge. However, some items on the BMTS improved (eg I worry that the transplant will not work) while others worsened (eg I get tired easily). It appears that use of the FACT-BMT will allow for an evaluation of different treatment effects over time and thus be useful in a QOL study attached to a clinical trial.
Significant pair-wise comparisons were observed for all patients measured at each time point for the following subscales, EWB, FWB, BMTS, and the FACT-G (Table 2) . When only those patients who were assessed at all four time points were reported (Table 3) , differences over the four time points were observed for PWB, and the overall FACT-BMT and not for the BMTS nor for the FACT-G. It is likely that some of this difference is due to the better PWB recorded at baseline and the significantly greater decrease at discharge on PWB in this group. On overall QOL as measured by the FACT-BMT, there was a 2.8 point greater mean score at baseline and a 2.3 point less mean score at discharge. Thus, there was a significant drop from baseline to discharge in this group which has been reflected in the physical well-being subscale as well. It appears that patients with better PWB scores were more likely to remain in the study, perhaps reflecting the fact that they were in better physical health at baseline. It could be that physical well-being at baseline is a predictor for survival or is a proxy for a number of other variables, eg stage of disease, previous treatment, age etc.
The overall quality of life in this sample at baseline (x = 85.2 (s.d. = 14.8)) compares favorably with the FACT-G standardization sample (x = 82.06 (s.d. = 15.9)) 30 and a sample of breast cancer patients prior to autologous bone marrow transplantation (x = 86.5 (s.d. = 13.9)). 16 On individual items of the FACT, reported 'lack of energy' decreased over time while at the same time the proportion of patients indicating that 'I tire easily' increased from baseline to 100 days and decreased slightly at 1 year. Even at 1 year, over 80% of patients reported that they tire easily. At 100 days and 1 year, 64 and 51% of the patients reported a 'lack of energy'. It is likely that patients can be improving in their overall energy level while at the same time 'tiring easily' when confronted with the tasks of daily living. This observation is supported by the mean energy rating that patients reported at the three time points following bone marrow transplantation. Up to 1 year following transplantation, the mean energy rating of patients returned to only 70% of normal. Patients rated the side-effects of treatment as less difficult over time and 87% of patient indicated satisfaction with their overall quality of life at 1 year. This supports the presence of a general trend or trajectory of recovery over the first year following BMT.
The proportion of patients with depressive symptoms at baseline (24%) is greater than the prevalence rates reported for people in the general population 35 and somewhat lower than the 31% reported in patients being evaluated prior to BMT. 36 At discharge and 100 days the proportion of patients with depressive symptoms increased to 28 and 31% respectively, while at 1 year, the number decreased to 20%. It appears that the time interval from baseline to discharge and discharge to 100 days represents a significant period of adjustment where depressive symptomatology may increase, even in a population that is free of disease and attempting to return to a normal life. It is likely that for some patients the failure to return to normal at the rate that they expected resulted in increased distress at 100 days. This relationship between patient expectations and psychological distress has been reported. 21 There is a general trend towards improvement in overall distress. Patients' POMS scores decreased from baseline to 1 year. At baseline, the mean score of 10.4 is similar to that of 10.8 observed in a general population of newly diagnosed cancer patients. 31 In general, overall distress for these BMT recipients decreased over time. The POMS scores, which provide a general measure of overall distress, decline over time from baseline to 1 year. This may appear to contradict the findings on the CES-D where the percentage of patients reporting depressive symptoms increases from baseline to 100 days and then decreases at 1 year. However, the mean scores on the POMS may obscure the fact that some patients may deteriorate and their scores may be obscured by the general trend of the group to have less overall distress. We conducted additional analyses to determine the percentage of patients that scored one standard deviation (s.d. = 6.9) above the mean of 10.4 (observed at baseline) at discharge, 100 days, and 1 year. Seventeen percent of this patient population had scores greater than 17.3 at 100 days and 16% had scores of 17.3 or higher at 1 year. Thus, there was a significant proportion of patients who have relatively high overall distress scores 1 year after BMT.
Patients' social support is uniformly high and remains so throughout the time trajectory from baseline to 1 year, when compared with the general population mean social support score of 70.1 (s.d. = 24.2). Tangible support measures the degree to which others help the patient on the tasks of daily living such as running errands, taking care of children, cleaning the house, and bringing in meals. However, there is a slight and statistically significant decline in overall support at 100 days and 1 year. On the specific subscales, the tangible support decreases significantly and shows a steady decline from baseline to 1 year. It may be that in the recovery trajectory, patients need less and request less tangible support over time, or it could be that supportive friends and family tire of providing this type of help to a person who appears to be normal, even though they may still be contending with the invisible disability of fatigue.
Patient concerns following transplantation show an interesting trend, particularly when compared with overall quality of life. While overall quality of life improves over time after discharge, the degree of concern in certain areas actually increases for most items over time. This may reflect the fact that when patients return to functional and physical well-being they have more energy to direct toward those concerns that face people in general. Stalker et al 29 found that cancer survivors had many concerns following treatment. When compared with the Stalker study of cancer survivors who had completed treatment less than 2 years prior to completing the survey of concerns, the BMT patient mean scores at 1 year were lower (less concern) on six items (job, family, health, state of mind, appearance and ability to have children) and higher (more concern) on five items (friends, financial concerns, physical well-being and planning for the future).
It appears that a subset of patients comprises the group that would be good candidates for psychological intervention at some time following discharge. The period between discharge and 100 days is a time when a number of patients are making significant adjustments in terms of physical energy lost, depressive symptoms and increasing concerns in particular areas. Twenty-two of sixty-four patients (34%) did report seeking individual counseling and/or participation in a support group following BMT, which may have served to reduce the overall distress and QOL deficits following BMT. This suggestive finding needs further research. Specifically, are there interventions that can positively influence QOL and psychological distress following BMT?
The study sample consists of 81% autologous and 19% allogeneic transplant patients. Other studies have reported results of allogeneic patients. 12, 14 While there is some conflicting evidence regarding the psychological and quality of life burdens of allogeneic vs autologous treatment, most clinicians agree that the demands of allogeneic transplantation with increased hospitalization time and the risk of GVHD comprise a more serious threat to overall quality of life than autologous BMT. While few differences were detected between autologous and allogenic patients, differences could exist and may not be measurable due to the small numbers of allogenic patients at 100 days and 1 year. In previous research, no difference between autologous and allogeneic transplants were recorded on the FACT-BMT. 27 We have documented three distinct recovery trajectories with quality of life and distress returning to near normal levels at 1 year even as patient concerns increase and specific problems persist, ie tiring easily. However, a significant number of patients reported psychological distress in the form of depressive symptoms and general distress at all time points and particularly at 100 days. This suggests two types of intervention. First, prior to transplant, patients should be informed of the likely temporal trajectory of their recovery and that the full effect of fatigue and energy depletion may conflict with their own expectations of returning to normal. It is likely that interventions that normalize the experience of low energy and other symptoms will contribute to the well-being of that portion of patients still struggling to return to normal following BMT. Psychoeducational interventions that begin prior to transplantation and continue throughout the 1 year time period would be useful to a substantial percentage of patients. It may be that these patients can be identified prior to transplantation or at 100 days so that interventions may be implemented. While patients at most transplant centers undergo pre-transplantation assessment, follow-up quality of life and psychological assessments are still rare. Even if it is impossible to predict which patients might become 'psychological casualties' it could be possible to schedule regular brief follow-up appointments for BMT patients with an oncology counselor. This could serve to identify patients in need of intervention. These interventions may be most useful sometime after discharge when patients begin to regain functional and physical abilities and have the psychological energy necessary to participate more fully in their own quality of life and emotional recovery.
